EBR Systems Says Engagement Leads to US CMS Initiating National Coverage Determination for LVEP in Cardiac Resynchronization Therapy

MT Newswires Live06-04

EBR Systems (ASX:EBR) said the US Centers for Medicare and Medicaid Services (CMS) initiated a National Coverage Determination to evaluate Medicare coverage for leadless left ventricular endocardial pacing (LVEP) used in cardiac resynchronization therapy, as a result of EBR's engagement with CMS through the Transitional Coverage for Emerging Technologies (TCET) pathway, according to a Thursday Australian bourse filing.

EBR is working toward CMS's projected timeline, which would deliver potential coverage determination approval for the Wireless Stimulation Endocardially (WiSE) system by early 2027.

Under the coverage determination process, CMS will conduct a national coverage analysis to study whether a medical technology meets the statutory standard of being reasonable and necessary for Medicare beneficiaries. A positive coverage determination outcome will support broader Medicare coverage, expanded patient access, and accelerated US commercialization efforts.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment